The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
39
ONO-2952 Active tablets, every day for 2 weeks
ONO-2952 Matching Placebo every day for 2 weeks
Boston Clinical Site
Boston, Massachusetts, United States
St. Louis Clinical Site
St Louis, Missouri, United States
Chapel Hill Clinical Site
Chapel Hill, North Carolina, United States
Oklahoma City Clinical Site
Oklahoma City, Oklahoma, United States
Change in pain intensity rating during rectal distention by using a numeric pain rating scale
Time frame: 2 weeks
Safety assessed through adverse events and clinical laboratory values
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.